Burton Alexander, MD
Hematology-Oncology · Norfolk, VANPI 1841293966
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $393 of the $612 with a category attached, or 64.2%. 9 manufacturers reported payments, led by Dova Pharmaceuticals at 40.3% of the total.
Across 13 payments — averaging $47.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$247
- Array Biopharma Inc$150
- Sanofi$104
- E.r. Squibb & Sons, L.L.C.$32
- Gilead$28
- Bayer$16
- plus $37 from 3 others
What the payments were for
- Speaking & faculty fees$15025%
- Food & beverage$39364%
- Education$6911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 3 | $247 |
| Array Biopharma Inc | 1 | $150 |
| Sanofi | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Gilead | 2 | $28 |
| Bayer | 1 | $16 |
| CSL Behring | 1 | $13 |
| Seagen Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 75 | $1,149,709 |
| CalquenceAcalabrutinib Maleate | 27 | $412,241 |
| JakafiRuxolitinib Phosphate | 12 | $195,855 |
| BrukinsaZanubrutinib | 13 | $194,603 |
| TavalisseFostamatinib Disodium | 13 | $178,194 |
| EliquisApixaban | 103 | $84,854 |
| XareltoRivaroxaban | 69 | $63,658 |
| Hydroxyurea | 60 | $1,932 |
| Acyclovir | 39 | $532 |
| Dexamethasone | 17 | $235 |
| Warfarin Sodium | 41 | $199 |
| Letrozole | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Norfolk
- Edward GeorgeNorfolk$323K
- Paul ConklingNorfolk$4K
- Michael LeeNorfolk$501
- Scott CrossNorfolk$388
- Ravneet GrewalLansdowne$10K
- John PascholdWilliamsburg$6K
- Valiant TanChesapeake$3K
- David PowellHampton$610
- John KesslerNewport News$194
- Kathryn CappellFairfax$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.